Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulio Metro

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
Translational Lung Cancer Research|March 26, 2015
Advances on EGFR mutation for lung cancerGiulio Metro, Lucio Crinò
Drugs in Context|July 20, 2018
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?Alfredo Addeo, Giulio Metro
Journal of Thoracic Disease|December 23, 2017
Adjuvant treatment of non-small cell lung cancer: focus on targeted therapyMarco Tazza, Giulio Metro
Expert Opinion on Emerging Drugs|August 22, 2009
Emerging drugs for small-cell lung cancerGiulio Metro, Federico Cappuzzo
European Respiratory Review : an Official Journal of the European Respiratory Society|March 5, 2014
Therapeutic options targeting angiogenesis in nonsmall cell lung cancerLucio Crinò, Giulio Metro
Expert Review of Anticancer Therapy|May 11, 2011
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancerGiulio Metro, Lucio Crinò
Expert Review of Anticancer Therapy|June 22, 2012
Novel molecular trends in the management of advanced non-small-cell lung cancerGiulio Metro, Lucio Crinò
Expert Opinion on Pharmacotherapy|September 23, 2008
HER-2-positive metastatic breast cancer: trastuzumab and beyondGiulio Metro, Marcella Mottolese, Alessandra Fabi
Current Opinion in Oncology|August 14, 2010
Supportive care in neurooncologyAndrea Pace, Giulio Metro, Alessandra Fabi
Drugs in Context|May 11, 2023
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasksAndrea De Giglio, Biagio Ricciuti, Giulio Metro
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
Translational Lung Cancer Research|March 26, 2015
Advances on EGFR mutation for lung cancerGiulio Metro, Lucio Crinò
Drugs in Context|July 20, 2018
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?Alfredo Addeo, Giulio Metro
Journal of Thoracic Disease|December 23, 2017
Adjuvant treatment of non-small cell lung cancer: focus on targeted therapyMarco Tazza, Giulio Metro
Expert Opinion on Emerging Drugs|August 22, 2009
Emerging drugs for small-cell lung cancerGiulio Metro, Federico Cappuzzo
European Respiratory Review : an Official Journal of the European Respiratory Society|March 5, 2014
Therapeutic options targeting angiogenesis in nonsmall cell lung cancerLucio Crinò, Giulio Metro
Expert Review of Anticancer Therapy|May 11, 2011
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancerGiulio Metro, Lucio Crinò
Expert Review of Anticancer Therapy|June 22, 2012
Novel molecular trends in the management of advanced non-small-cell lung cancerGiulio Metro, Lucio Crinò
Expert Opinion on Pharmacotherapy|September 23, 2008
HER-2-positive metastatic breast cancer: trastuzumab and beyondGiulio Metro, Marcella Mottolese, Alessandra Fabi
Current Opinion in Oncology|August 14, 2010
Supportive care in neurooncologyAndrea Pace, Giulio Metro, Alessandra Fabi
Drugs in Context|May 11, 2023
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasksAndrea De Giglio, Biagio Ricciuti, Giulio Metro
Pageof 17